Jazz Pharmaceuticals's total inventories for the quarter that ended in Mar. 2026 was MXN7,889 Mil. Jazz Pharmaceuticals's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was MXN7,698 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Jazz Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was MXN-1,037.39.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Jazz Pharmaceuticals's Days Inventory for the
three
months ended in Mar. 2026 was 290.50.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Jazz Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.31.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Jazz Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.40.
Jazz Pharmaceuticals (MEX:JAZZN) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Jazz Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Jazz Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Jazz Pharmaceuticals Total Inventories Related Terms
Jazz Pharmaceuticals Total Inventories Historical Data
* Premium members only.
The historical data trend for Jazz Pharmaceuticals's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of MXN7,889 Mil mean?
Jazz Pharmaceuticals (MEX:JAZZN) has a Total Inventories of MXN7,889 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' Total Inventories too high?
Jazz Pharmaceuticals' current Total Inventories is MXN7,889 Mil. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Total Inventories compare to ASND and SMMT?
Jazz Pharmaceuticals' Total Inventories of MXN7,889 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Total Inventories is MXN7,889 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Jazz Pharmaceuticals (MEX:JAZZN) has a current Total Inventories of MXN7,889 Mil. The stock's GF Value™ is MXN1,641.59, compared to a current price of MXN2,500.00 — trading 52.3% above its estimated fair value. The current Total Inventories is MXN7,889 Mil. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Jazz Pharmaceuticals (MEX:JAZZN), the current Total Inventories is MXN7,889 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (MEX:JAZZN) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN2,500.00 is trading 52.3% above its estimated GF Value™ of MXN1,641.59.
Key valuation signals for MEX:JAZZN:
Total Inventories: MXN7,889 Mil
GF Value™: MXN1,641.59 vs. price of MXN2,500.00 (52.3% above fair value)
No single metric tells the full story. See the MEX:JAZZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score
Get the complete analysis for MEX:JAZZN
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:JAZZN has been successfully added to your 
